Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03635892 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
A Phase 2 study of Chromophobe Renal Cell Carcinoma and Papillary Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT03635892: Active Phase 2 study of Chromophobe Renal Cell Carcinoma and Papillary Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03635892 is a Phase 2 study of Chromophobe Renal Cell Carcinoma and Papillary Renal Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, below the 226-participant average among 8 other Chromophobe Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03635892, a Phase 2 study of Chromophobe Renal Cell Carcinoma and Papillary Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.
Primary Outcome
per RECIST v1.1
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG cabozantinib
Study Locations (7)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT03635892 still lists
NCT03635892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 226-participant average among 8 other Chromophobe Renal Cell Carcinoma trials with a reported enrollment target (73% lower).
The record links to 7 conditions, with Chromophobe Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which nivolumab is the first listed.
NCT03635892 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT03635892 about?
NCT03635892 is a clinical study titled "A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma". The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.
What is the current status of trial NCT03635892?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2018-08-13. Estimated completion is 2026-08.
What conditions does trial NCT03635892 study?
This clinical trial studies the following conditions: Chromophobe Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma.
What interventions are being tested in trial NCT03635892?
The interventions under investigation include: nivolumab (DRUG), cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03635892?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03635892 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chromophobe Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03635892's enrollment target sits among peer trials
60 6th of 8 higher than 2 of 8 other Chromophobe Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chromophobe Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RECRUITING · Phase 2
-
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI